Using mesenchymal stem cells during allogeneic stem cell transplantation
Official title: Co-transplantation of Mesenchymal Stromal Cells in Allogeneic Hematopoietic Stem Cell Transplantation
Run by Fujian Medical University · NCT04247945 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing whether adding mesenchymal stem cells to a stem cell transplant can help patients recover better and reduce complications like graft versus host disease.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | Any age to 65 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Fujian Medical University Academic / other |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT04247945 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals under 65 years old who are eligible for allogeneic stem cell transplantation and have adequate organ function.
✕Probably not a fit
Patients who are pregnant, lactating, or have significant co-morbidities that prevent MSC administration may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effects of co-transplanting mesenchymal stem cells (MSCs) alongside allogeneic hematopoietic stem cell transplantation (allo-HSCT). The research aims to evaluate how MSC infusion may enhance engraftment, reduce the incidence of graft versus host disease (GVHD), and improve overall survival rates post-transplant. By focusing on the immunomodulatory and anti-inflammatory properties of MSCs, the study seeks to determine their potential benefits in the transplant process.
Why it matters
Potential benefit: If successful, this approach could lead to improved transplant outcomes and reduced complications for patients undergoing allo-HSCT.
How similar studies have gone: Other studies have shown promising results with MSCs in transplant settings, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Signed written informed consent * Aged \<65 years * Willing to transplant * Cardiac: Left ventricular ejection fraction ≥ 50% * Adequate renal and hepatic function * Performance status: Karnofsky ≥ 70% Exclusion Criteria: * Pregnant or lactating females. * Any co-morbidity precluding the administration of MSCs.
Where it's running
-
Union Hospital,Fujian Medical University
Fuzhou, Fujian, China Recruiting
Study contacts
- Study coordinator: Ting Yang, Prof.
- Email: yang.hopeting@gmail.com
- Phone: +86-591-86218041
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Long-term心理 and cognitive check after stem cell transplant for immune deficiencies
This study tests the long-term neurocognitive and psychological functioning of 6–8 year-old children who had an allogeneic stem cell transplant for a primary immune deficiency, at least two years after the transplant.
-
Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia
This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.
-
Moxibustion with second-line treatment for steroid-refractory acute graft-versus-host disease after transplant
This study will test whether adding moxibustion to standard second-line drug therapy helps people aged 14–65 with steroid-refractory gastrointestinal acute GVHD after an allogeneic stem cell transplant.
-
Baricitinib for persistent low platelets after stem cell transplant
We’re testing baricitinib to see if it can help people with long-term low platelets after an allogeneic stem cell transplant who didn’t respond to other treatments.
-
Adding venetoclax to fludarabine–melphalan conditioning for people over 50 with AML or MDS getting a donor stem cell transplant
This tests whether adding venetoclax to standard fludarabine–melphalan conditioning helps people over 50 with AML or MDS who are having an allogeneic stem cell transplant.
-
Cardiovascular problems after allogeneic stem cell transplant
This study looks at heart-related problems after allogeneic hematopoietic stem cell transplantation to see how often they occur and what factors might predict them.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.